Literature DB >> 24100755

Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact.

Yun-Hsuan Lee1, Chia-Yang Hsu, Yi-Hsiang Huang, Cheng-Yuan Hsia, Yi-You Chiou, Chien-Wei Su, Han-Chieh Lin, Teh-Ia Huo.   

Abstract

GOALS/
BACKGROUND: Macrovascular invasion (MaVI) is often detected by radiologic imaging in hepatocellular carcinoma (HCC) patients and may affect their long-term survival. We aimed to investigate the prevalence, determinants, and prognostic impact of MaVI in patients with HCC receiving curative and noncurative therapies. STUDY: A total of 2654 HCC patients in a single center were identified. The risk factors and prognostic determinants of MaVI were determined.
RESULTS: A total of 928 (35%) patients had MaVI. Old age, lower serum α-fetoprotein level, higher serum sodium level, good performance status, smaller total tumor volume, and better liver functional reserve were significantly associated with a lower risk for VI. In the Cox proportional hazards model, patients with lower serum albumin level, higher serum bilirubin and α-fetoprotein level, worse performance status, the presence of ascites, and MaVI independently predicted a decreased long-term survival in patients undergoing both curative and noncurative treatments. In addition, lower sodium level and larger tumor size were independently associated with a poor outcome in the noncurative treatment group. Of the patients with MaVI, the 1-year survival rates for patients receiving surgical treatment, local ablation, transarterial chemoembolization, and supportive care were 83%, 75%, 57%, and 24%, respectively (P<0.001).
CONCLUSIONS: MaVI represents a distinct tumor phenotype of HCC and is associated with younger age, aggressive tumor behavior, poor liver functional reserve, and poor performance status. It adversely affects the survival of HCC patients independent of treatment strategy. Intensive anticancer therapy should be proposed to achieve a better long-term survival for the at-risk patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24100755     DOI: 10.1097/MCG.0b013e3182a8a254

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  31 in total

1.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

2.  From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma.

Authors:  Ghaith Abu-Zeinah; Dwight Owen; Carlos Prieto-Granada; Natasha Rekhtman; David Klimstra; Dipti Gupta; James Harding; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2014-05

3.  Upfront surgery.

Authors:  Jong Man Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-06-30

4.  The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study.

Authors:  Chaobin He; Yize Mao; Jun Wang; Yunda Song; Xin Huang; Xiaojun Lin; Shengping Li
Journal:  J Gastrointest Surg       Date:  2018-04-17       Impact factor: 3.452

Review 5.  Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis.

Authors:  Maxime Ronot; Yvonne Purcell; Valérie Vilgrain
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 6.  Tumor thrombus: incidence, imaging, prognosis and treatment.

Authors:  Keith Bertram Quencer; Tamir Friedman; Rahul Sheth; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

7.  A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Hao-Jan Lei; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Dig Dis Sci       Date:  2019-10-28       Impact factor: 3.199

8.  Finally, a Minimally Invasive Option for Intrahepatic Inferior Vena Cava Invasion by Hepatocellular Carcinoma.

Authors:  Erik Soule; Jerry Matteo
Journal:  Gastrointest Tumors       Date:  2018-08-17

9.  Dual hepatitis B and C-associated hepatocellular carcinoma: clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade.

Authors:  Chih-Chieh Ko; Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Hao-Jan Lei; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Int J Clin Oncol       Date:  2022-02-04       Impact factor: 3.402

10.  Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers.

Authors:  Maya S Krishnan; Anand Rajan Kd; Jangho Park; Vinodhini Arjunan; Fernando Jose Garcia Marques; Abel Bermudez; Olivia A Girvan; Nam S Hoang; Jun Yin; Mindie H Nguyen; Nishita Kothary; Sharon Pitteri; Dean W Felsher; Renumathy Dhanasekaran
Journal:  Hepatology       Date:  2021-05-08       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.